Patents by Inventor Liming GUO

Liming GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240240168
    Abstract: The present disclosure relates to a recombinant BoNT/A and a preparation method thereof. The recombinant BoNT/A is a BoNT/A mutant, the BoNT/A mutant comprising a first peptide fragment and a second peptide fragment, which are linked through an interchain disulfide bond; wherein the first peptide fragment has a mutation at position 134 and/or position 165 compared to the light chain of a wild-type BoNT/A; and/or the second peptide fragment has at least one of the following mutation positions compared to the heavy chain of the wild-type BoNT/A: positions 791, 967, and 1060. The method includes: subjecting the first peptide fragment to a first renaturation treatment to obtain a first denatured product, subjecting the second peptide fragment to a second denaturation treatment to obtain a second denatured product, and subjecting the first denatured product and the second denatured product to a renaturation and assembly treatment to obtain the BoNT/A mutant.
    Type: Application
    Filed: March 22, 2024
    Publication date: July 18, 2024
    Applicant: JHM BIOPHARMACEUTICAL (HANGZHOU) CO., LTD.
    Inventors: Yubao SHEN, Guoqing BAO, Liming GUO
  • Publication number: 20230406901
    Abstract: The present disclosure relates to a growth hormone fusion protein and a preparation method and use thereof. The growth hormone fusion protein includes: a double-stranded structure having a first constant region Fc segment and a second constant region Fc segment; and a growth hormone linked to the first constant region Fc segment, the growth hormone has no methionine at an N-terminus thereof, and the growth hormone fusion protein was expressed by a non-mammalian cell expression system. According to the present disclosure, by adopting the fusion of the growth hormone and the double-stranded structure, the in vivo half-life of the growth hormone can be prolonged, and since each double-stranded structure only carries one growth hormone, the active site of the growth hormone is not affected by steric hindrance, and stronger activity is provided, and since the N-terminus of the growth hormone has no methionine, higher safety is provided.
    Type: Application
    Filed: March 6, 2023
    Publication date: December 21, 2023
    Applicant: JHM BIOPHARMACEUTICAL (HANGZHOU) CO., LTD.
    Inventors: Guoqing BAO, Liming GUO, Yubao SHEN, Xin GAO, Jianan Li, Chao WANG, Qi WU, Baocai SUN